Results 151 to 160 of about 935,031 (288)

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Savor the flavor: A randomized double-blind study assessing taste-enhanced placebo analgesia in healthy volunteers. [PDF]

Clin Transl Sci, 2022
Zunhammer M, Goltz G, Schweifel M, Stuck BA, Bingel U.   +4 more
europepmc   +1 more source

The Relationship Between Dissociated Measures of Inhibition and Hypnotic and Placebo Analgesia Effects.

OBJECTIVE: The aim of the present research was to assess the relationship between the executive function of inhibition and hypnotic and placebo analgesia.
Guestini, Alethea, Parris, Benjamin A.
core   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Neural Correlates of Placebo Analgesia and Emotion Regulation: A Coordinate-Based Neuroimaging Meta-Analysis

Nature-Nurture Journal of Psychology
Background: Placebo analgesia and emotion regulation engage overlapping cognitive and affective mechanisms, yet the extent of shared versus distinct neural circuits remains unclear.
Javeria Noor, Dr. Muhammad Aqeel
doaj   +1 more source

Re‐thinking peripheral dysfunctions in obesity: The emerging role of sulphaceutics and sulphanutraceutics

British Journal of Pharmacology, EarlyView.
Obesity is a chronic, relapsing, multisystem disease in which cardiometabolic risk arises from excess adiposity and progressive dysfunction of peripheral organs, ultimately disrupting endocrine and metabolic crosstalk among tissues. Within this network, sulphur‐based biology, centred on hydrogen sulphide and related reactive sulphur species, has ...
Martina Smimmo, Veronica Casale, Roberta d'Emmanuele di Villa Bianca, Valentina Vellecco, Mariarosaria Bucci   +4 more
wiley   +1 more source

[Neurobiological and neurochemical mechanisms of placebo analgesia]. [PDF]

Schmerz, 2022
Asan L, Bingel U, Kunkel A.
europepmc   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Experience with opioids does not modify the brain network involved in expectations of placebo analgesia. [PDF]

Eur J Neurosci, 2022
Wicht CA, Mouthon M, Nsimire Chabwine J, Gaab J, Spierer L.   +4 more
europepmc   +1 more source

GLP‐1 receptor activation attenuates chronic migraine‐like behaviour: Sex‐specific modulation of opioid‐ and endocannabinoid‐related pathways

British Journal of Pharmacology, EarlyView.
Background and Purpose Chronic migraine (CM) is a highly disabling condition that remains suboptimally treated. Metabolic disturbances may trigger migraine chronification, whereas impaired endogenous pain inhibition contributes to CM development. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), used for type 2 diabetes and obesity, show efficacy ...
Katarina Sićović, Katarina Nastić, Miroslav Dinić, Emilija Brdarić, Uroš Pecikoza, Maja Tomić, Ana Micov   +6 more
wiley   +1 more source